THERANEXUS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.135 EUR | +1.34% |
|
+8.10% | +1.34% |
| Apr. 19 | Theranexus: share price rises following promising trial results | CF |
| Mar. 11 | Theranexus: CEO takes over as Chairman of the Board | CF |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 55.9 | 11.01 | 69.06 | 22.62 | 9.356 | 8.806 |
| Enterprise Value (EV) 1 | 44.19 | 1.56 | 69.06 | 15.42 | 5.137 | 8.806 |
| P/E ratio | -10.5 x | -1.97 x | -15.9 x | -3.06 x | - | -1.13 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 319,400,240 x | 17,847,869 x | 219,224,178 x | 904,957,200 x | 7,508,726 x | - |
| EV / Revenue | 319,400,173 x | 17,847,853 x | 219,224,178 x | 904,956,912 x | 7,508,722 x | - |
| EV / EBITDA | -8,059,846 x | -1,524,592 x | -12,066,332 x | -2,723,149 x | -1,579,049 x | - |
| EV / FCF | -9,526,355 x | -1,556,803 x | - | -3,672,762 x | -1,716,704 x | - |
| FCF Yield | -0% | -0% | - | -0% | -0% | - |
| Price to Book | 4.17 x | - | - | 2.44 x | 2.99 x | - |
| Nbr of stocks (in thousands) | 3,119 | 3,622 | 3,703 | 4,570 | 5,346 | 7,759 |
| Reference price 2 | 17.92 | 3.040 | 18.65 | 4.950 | 1.750 | 1.135 |
| Announcement Date | 4/17/19 | 4/9/20 | 4/7/21 | 4/25/22 | 4/12/23 | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | 0.175 | 0.617 | 0.315 | 0.025 | 1.246 | - |
| EBITDA | -6.935 | -7.223 | -5.723 | -8.308 | -5.925 | - |
| EBIT | -6.99 | -7.377 | -6.099 | -9.512 | -6.257 | - |
| Operating Margin | -3,994.29% | -1,195.62% | -1,936.19% | -38,048% | -502.17% | - |
| Earnings before Tax (EBT) | -7.021 | - | - | - | - | - |
| Net income | -5.301 | -5.58 | -4.797 | -8.15 | -6.567 | - |
| Net margin | -3,029.14% | -904.38% | -1,522.86% | -32,600% | -527.05% | - |
| EPS 1 | -1.699 | -1.540 | -1.174 | -1.620 | - | -1.005 |
| Free Cash Flow | -5.867 | -7.074 | - | -6.16 | -5.45 | - |
| FCF margin | -3,352.81% | -1,146.44% | - | -24,639.68% | -437.39% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/17/19 | 4/9/20 | 4/7/21 | 4/25/22 | 4/12/23 | - |
1EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 17.8 | 11.7 | 6.67 | 5.51 | 7.2 | 4.22 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.65 | -5.02 | -6.42 | -4.89 | -4.59 | -2.54 |
| ROE (net income / shareholders' equity) | -21.9% | -33% | -47.7% | -47.4% | -79.7% | -82.6% |
| ROA (Net income/ Total Assets) | -14.6% | -22.3% | -26.9% | -23.2% | -34.6% | -27% |
| Assets 1 | 14.47 | 23.79 | 20.71 | 20.67 | 23.55 | 24.3 |
| Book Value Per Share 2 | 6.000 | 4.300 | 2.750 | 2.520 | 2.030 | 1.070 |
| Cash Flow per Share 2 | 1.030 | 2.290 | 0.9500 | 2.130 | 1.100 | 0.3900 |
| Capex 1 | 0.01 | 0.01 | 0.98 | 0 | 0.02 | 0.04 |
| Capex / Sales | 5.93% | 7.85% | 173.82% | 0.62% | 2,546.51% | 9.93% |
| Announcement Date | 4/27/18 | 5/2/19 | 4/30/20 | 4/29/21 | 4/29/22 | 4/12/23 |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.135
EUR
Average target price
4
EUR
Spread / Average Target
+252.42%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.34% | 9.4M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALTHX Stock
- Financials Theranexus
